Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 24, 2023, Philips reported a solid start to the year with Q1 sales rising to EUR 4.2 billion, reflecting a 6% increase in comparable sales. However, the company faced a loss of EUR 583 million due to restructuring provisions and litigation expenses, primarily related to a EUR 575 million provision for a US class action concerning Respironics recalls. Adjusted EBITA improved to EUR 359 million (8.6% of sales), up from EUR 243 million in Q1 2022. Despite flat order intake, the order book grew by 10% year-over-year. The Diagnosis & Treatment segment achieved a 15% increase in comparable sales, while Personal Health saw a 6% decline. The company also plans to simplify its operating model and has reduced its workforce by 5,400 roles as part of its restructuring plan.